ECSP034624A - Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa - Google Patents

Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa

Info

Publication number
ECSP034624A
ECSP034624A EC2003004624A ECSP034624A ECSP034624A EC SP034624 A ECSP034624 A EC SP034624A EC 2003004624 A EC2003004624 A EC 2003004624A EC SP034624 A ECSP034624 A EC SP034624A EC SP034624 A ECSP034624 A EC SP034624A
Authority
EC
Ecuador
Prior art keywords
pro
drug
agonist
sdi
combinations
Prior art date
Application number
EC2003004624A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP034624A publication Critical patent/ECSP034624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a composiciones farmacéuticas que comprenden combinaciones de un agonista GABA, un pro fármaco del mismo o una sal farmacéutica mente aceptable de dicho agonista de GABA o dicho pro fármaco y un SDI, un pro fármaco del mismo, o una sal farmacéuticamente aceptable de dicho agonista de GABA o dicho pro fármaco y un SDI, un pro fármaco del mismos o una sal farmacéutica mente aceptable de dicho SDI o dicho pro fármaco, estuches que contienen tales combinaciones y métodos para utilizar tales combinaciones en el tratamiento de mamíferos, incluidos los seres humanos que padecen complicaciones de la diabetes tales como neuropatía diabética, cardiomiopatía diabética, retinopatía diabética, microangiopatia diabética, cataratas o úlceras de los pies.
EC2003004624A 2000-11-30 2003-05-27 Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa ECSP034624A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
ECSP034624A true ECSP034624A (es) 2003-07-25

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004624A ECSP034624A (es) 2000-11-30 2003-05-27 Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa

Country Status (38)

Country Link
US (1) US6544998B2 (es)
EP (1) EP1337271B1 (es)
JP (1) JP2004514699A (es)
KR (1) KR20030059290A (es)
CN (1) CN1477975A (es)
AP (1) AP2001002360A0 (es)
AR (1) AR031431A1 (es)
AT (1) ATE281181T1 (es)
AU (1) AU2002215159A1 (es)
BG (1) BG107774A (es)
BR (1) BR0115783A (es)
CA (1) CA2430298A1 (es)
CR (1) CR6964A (es)
CZ (1) CZ20031399A3 (es)
DE (1) DE60106968T2 (es)
DO (1) DOP2001000289A (es)
EA (1) EA200300432A1 (es)
EC (1) ECSP034624A (es)
EE (1) EE200300248A (es)
ES (1) ES2230378T3 (es)
HR (1) HRP20030420A2 (es)
HU (1) HUP0302160A3 (es)
IL (1) IL155704A0 (es)
IS (1) IS6786A (es)
MA (1) MA26964A1 (es)
MX (1) MXPA03004870A (es)
NO (1) NO20032441L (es)
OA (1) OA12534A (es)
PA (1) PA8534101A1 (es)
PE (1) PE20020597A1 (es)
PL (1) PL365927A1 (es)
PT (1) PT1337271E (es)
SK (1) SK6192003A3 (es)
SV (1) SV2003000751A (es)
TN (1) TNSN01169A1 (es)
UY (1) UY27042A1 (es)
WO (1) WO2002043762A2 (es)
ZA (1) ZA200303381B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
DE60213592T2 (de) * 2001-05-25 2007-08-09 Warner-Lambert Co. Llc Flüssige pharmazeutische zusammensetzung
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
KR20070020022A (ko) * 2004-04-02 2007-02-16 임팩스 라보라토리즈, 인코포레이티드 Ｇａｂａ 수용체 효능제에 대한 제어 방출 제형
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
EP2607362B1 (en) 2005-02-17 2014-12-31 Astellas Pharma Inc. Piperidine and piperazine carboxylates as FAAH inhibitors
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
DK2142529T3 (da) * 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
AU2008310114B2 (en) * 2007-10-09 2014-01-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
EP2621282B1 (en) * 2010-09-28 2020-04-15 The Regents of The University of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
SG10201605163PA (en) 2011-06-22 2016-08-30 Purdue Pharma Lp Trpv1 antagonists including dihydroxy substituent and uses thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
AR227521A1 (es) 1979-06-01 1982-11-15 Wellcome Found Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
WO2000050034A1 (en) * 1999-02-24 2000-08-31 The Regents Of The University Of California Gaba receptors mediate inhibition of t cell responses
KR20020005653A (ko) * 1999-04-01 2002-01-17 실버스타인 아써 에이. 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘
DE60009777T2 (de) * 1999-04-01 2004-08-19 Pfizer Products Inc., Groton Verbindung für Behandlung und Vorsorge bei Diabetes

Also Published As

Publication number Publication date
NO20032441D0 (no) 2003-05-28
NO20032441L (no) 2003-07-03
EP1337271A2 (en) 2003-08-27
CA2430298A1 (en) 2002-06-06
AU2002215159A1 (en) 2002-06-11
EA200300432A1 (ru) 2003-10-30
TNSN01169A1 (fr) 2005-11-10
ES2230378T3 (es) 2005-05-01
HUP0302160A2 (hu) 2003-11-28
DE60106968T2 (de) 2005-11-03
IS6786A (is) 2003-04-14
AP2001002360A0 (en) 2001-12-31
MXPA03004870A (es) 2003-08-19
BR0115783A (pt) 2003-09-16
UY27042A1 (es) 2002-07-31
CN1477975A (zh) 2004-02-25
JP2004514699A (ja) 2004-05-20
CZ20031399A3 (cs) 2004-04-14
DE60106968D1 (de) 2004-12-09
SK6192003A3 (en) 2004-07-07
PL365927A1 (en) 2005-01-10
HRP20030420A2 (en) 2004-08-31
DOP2001000289A (es) 2003-02-15
PT1337271E (pt) 2005-01-31
WO2002043762A3 (en) 2003-03-13
IL155704A0 (en) 2003-11-23
HUP0302160A3 (en) 2005-05-30
EP1337271B1 (en) 2004-11-03
OA12534A (en) 2006-06-05
US20020091128A1 (en) 2002-07-11
ZA200303381B (en) 2004-04-30
SV2003000751A (es) 2003-01-13
BG107774A (en) 2004-01-30
PE20020597A1 (es) 2002-07-08
WO2002043762A2 (en) 2002-06-06
KR20030059290A (ko) 2003-07-07
PA8534101A1 (es) 2002-10-31
EE200300248A (et) 2003-10-15
US6544998B2 (en) 2003-04-08
AR031431A1 (es) 2003-09-24
ATE281181T1 (de) 2004-11-15
CR6964A (es) 2004-02-02
MA26964A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
ECSP034624A (es) Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa
DOP2001000294A (es) Combinación de agonistas de gaba e inhibidores de aldosa-reductasa
AR067347A1 (es) Combinacion antihelmintica
MX2021008358A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
PA8615301A1 (es) Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
UY28231A1 (es) Metodos y composiciones farmacéuticas para la obtención confiable de niveles aceptables de testosterona en suero.
CY1112269T1 (el) Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
PA8515601A1 (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos
AR128464A1 (es) Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada
CL2025000581A1 (es) Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren
CO2022001218A2 (es) Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso
AR055628A1 (es) Dipositivos de administracion transdermicas de farmacos que contienen o- desmetilvenlafaxina (odv) o sus sales
CY1114480T1 (el) Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
PE20020907A1 (es) Combinacion de taxano y una cinasa dependiente de la ciclina
AR046213A1 (es) Forma de presentacion del naproxeno sodico
AR067351A1 (es) Combinacion de picotamida con nafronil
AR048958A1 (es) Medicamento en forma de pelicula para administracion por via oral, que contiene estriol